HC Wainwright reiterates Buy on Biomea Fusion with $4 price target

what happened

HC Wainwright & Co. reaffirmed its Buy rating on Biomea Fusion shares and kept a $4.00 price target. That target implies 217.5% upside from the October 13 close of $1.26, according to reference data provided by Benzinga.

The analyst note points to progress in the company's clinical programs. It highlights the OPAL study, which is testing icovamenib alongside semaglutide for obesity. Preclinical results suggest this combination could enhance metabolic benefits and help preserve lean mass.

The analysts also flagged Phase 1 data for BMF-650, Biomea's next-generation oral GLP-1 receptor agonist. The data showed steady weight reduction and good tolerability, which lays groundwork for further clinical evaluation and possible strategic partnerships.

why it matters

For the market, this signals that investors are watching how Biomea's obesity pipeline advances. The new BMF-650 data adds another milestone that could matter when assessing the company's outlook.

tags

instruments